STOCK TITAN

BioAdaptives Q3 2026 loss widens to $1.50M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

BioAdaptives, Inc. (BDPT) reported third-quarter 2026 revenue of $4,993 and a net loss of $1,498,315, versus $4,632 revenue and a $379,502 loss a year earlier. For the nine months ended September 30, 2026, revenue was $15,495 versus $7,851, while net loss was $1,459,311 versus $734,552. The quarter’s fair-value loss on derivative liabilities was $1,420,251, versus $201,360.

Cash was $5,144 at September 30, 2026. Net cash used in operating activities was $242,755 for the nine months, versus $360,197 in 2025. The company said cash was insufficient to fund operations at current levels for the next 12 months and disclosed substantial doubt about its ability to continue as a going concern; its accumulated deficit was $12,180,515.

Management found financial-reporting controls ineffective, citing inadequate duty segregation and risk assessment and insufficient written accounting policies; remediation depends on additional financing. BioAdaptives reported its 12% debentures issued in 2018 and due at various times in 2020 remained in default. On October 29, 2026, it executed a purchase agreement with Xycota Biosciences, LLC: Xycota would become a wholly owned subsidiary at closing, and the agreement also provided for a possible nutraceutical spin-off.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

4 major · 4 points

How the balance works

Positive

  • Moderate pointNine-month revenue rose to $15,495 from $7,851 in 2025.
  • Moderate pointOperating cash used declined to $242,755 from $360,197.

Negative

  • Major pointQuarterly net loss increased to $1,498,315 from $379,502.
  • Major pointSubstantial doubt about going concern; September 30 cash was $5,144.
  • Major pointFinancial-reporting controls remained ineffective due to material weaknesses at September 30, 2026.
  • Major point2018-issued 12% debentures due in 2020 remained in default.

Filing Explained

Debt conversions had already diluted existing holders; future share issuance remains a plan, while 2026 notes retain holder-controlled, price-linked conversion terms.

BioAdaptives reports that debt conversions during the nine months ended September 30, 2026 resulted in 206,668,852 newly issued common shares; it had 223,677,577 common shares outstanding then, versus 12,008,725 at December 31, 2025, reducing existing holders’ percentage ownership absent offsetting changes.

At September 30, total convertible-note principal was $726,500, with a $515,887 balance-sheet carrying amount after discount; the 2026 notes were issued with $289,100 principal for $239,000 in cash proceeds. For those 2026 notes, holders may convert at their option, with one note convertible only after 180 days, at 65% of the lowest traded price in the applicable 10- or 20-trading-day period, making the resulting share amount dependent on the conversion terms and amount converted.

Management also says it plans to issue additional common shares for cash and services during the next 12 months, but reports no formal commitments or arrangements for stock sales or loans.

Revenue (nine months) $15,495 Nine months ended September 30, 2026; $7,851 in 2025.
Revenue (quarter) $4,993 Three months ended September 30, 2026; $4,632 in 2025.
Net loss (quarter) $1,498,315 Three months ended September 30, 2026; $379,502 in 2025.
Net loss (nine months) $1,459,311 Nine months ended September 30, 2026; $734,552 in 2025.
Derivative fair-value loss (quarter) $1,420,251 Three months ended September 30, 2026; $201,360 in 2025.
Cash $5,144 As of September 30, 2026.
Net cash used in operating activities $242,755 Nine months ended September 30, 2026; $360,197 in 2025.
Common shares issued and outstanding 223,677,577 shares As of September 30, 2026.
going concern financial
"substantial doubt about its ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
material weaknesses regulatory
"identified the following material weaknesses in our internal control"
Material weaknesses are significant flaws in a company’s systems for ensuring its financial reports are accurate and reliable. Like a broken lock on a safe, they increase the chance that financial statements contain big errors or omissions, which can mislead investors about performance and risk; discovering one often raises questions about management oversight, may lead to restated results, and can affect investor confidence and a company’s valuation.
derivative liabilities financial
"change in fair value of derivative liabilities"
Derivative liabilities are obligations a company records when it owes money under financial contracts whose value depends on something else, like interest rates, stock prices, or currencies. Think of them as bets or insurance policies that can create future cash payments; they matter to investors because they can cause sudden changes in a company’s reported debt, profits and cash flow and reveal exposure to market risks that could affect valuation.
original issue discounts financial
"net of original issue discounts and financing costs"
Level 3 fair value measurement financial
"determined our derivative liabilities to be a Level 3 fair value measurement"
anti-dilutive financial
"excluded from the computation of diluted net loss per share as the result was anti-dilutive"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BDPT report in revenue and net loss for Q3 2026?

BDPT reported $4,993 in third-quarter revenue and a $1,498,315 net loss for the three months ended September 30, 2026. A year earlier, revenue was $4,632 and net loss was $379,502.

What are the terms of BioAdaptives’ 2026 convertible notes?

BioAdaptives issued $289,100 in principal amount of convertible notes for $239,000 in cash proceeds, net of original issue discounts and financing costs. The notes have terms of approximately 10 months to one year and annual interest rates of 10% to 12%. Holders may convert at prices based on 65% of the lowest traded price during the prior 10 or 20 trading days; one note is convertible 180 days after issuance.

What did BioAdaptives agree to do with Xycota Biosciences?

On October 29, 2026, BioAdaptives executed a purchase agreement with Xycota Biosciences, LLC. At closing, Xycota would become a wholly owned subsidiary and continue under its existing executive and scientific leadership; the agreement also provided for a possible nutraceutical spin-off.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

Commission File Number 000-54949

 

GRAPHIC

 

BioAdaptives Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

46-2592228

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

 

 

2620 Regatta Drive, Suite 102, Las Vegas, NV

 

89128

(Address of principal executive offices)

 

(Zip Code)

 

(702) 659-8829

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes     ☐ NO

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes     ☐ NO

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

☐

Large accelerated filer

☐

Accelerated filer

☐

Non-Accelerated filer

☒

Smaller reporting Company

 

 

☐

Emerging Growth Company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ YES     ☒ NO

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

223,677,511 common shares issued and outstanding as of November 6, 2026

 

 

 

 

Form 10-Q

Table of Contents

 

PART I – FINANCIAL INFORMATION

 

 

 

 

 

 

 

Item 1.

Financial Statements

 

3

 

 

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of operation

 

18

 

 

 

 

 

 

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

 

23

 

 

 

 

 

 

Item 4.

Controls and Procedures

 

23

 

 

 

 

 

 

PART II – OTHER INFORMATION

 

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

25

 

 

 

 

 

 

Item 1A.

Risk Factors

 

25

 

 

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

25

 

 

 

 

 

 

Item 3.

Defaults Upon Senior Securities

 

25

 

 

 

 

 

 

Item 4.

Mine Safety Disclosure

 

25

 

 

 

 

 

 

Item 5.

Other Information

 

25

 

 

 

 

 

 

Item 6.

Exhibits

 

26

 

 

 

 

 

 

Signature

 

27

 

 

 
2

Table of Contents

 

BIOADAPTIVES, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash

 

$5,144

 

 

$158,445

 

Inventory

 

 

34,197

 

 

 

44,706

 

Security deposit

 

 

-

 

 

 

2,500

 

Prepaid expense

 

 

8,665

 

 

 

6,250

 

Total Current Assets

 

 

48,006

 

 

 

211,901

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

9,500

 

 

 

14,000

 

TOTAL ASSETS

 

$57,506

 

 

$225,901

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

 

292,190

 

 

 

232,725

 

Derivative liabilities

 

 

1,861,614

 

 

 

1,738,804

 

Convertible notes

 

 

515,887

 

 

 

352,332

 

Notes Payable

 

 

32,096

 

 

 

32,096

 

Due to related party

 

 

2,978

 

 

 

-

 

Total Current Liabilities

 

 

2,704,765

 

 

 

2,355,957

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

2,704,765

 

 

 

2,355,957

 

 

 

 

 

 

 

 

 

 

Stockholders' Deficit:

 

 

 

 

 

 

 

 

Preferred stock, ($.0001 par value, 31,000,000 shares authorized;

 

 

 

 

 

 

 

 

Series A Preferred Stock 4,000,000 shares designated; 11,167 shares issued and outstanding as of September 30, 2026 and December 31, 2025

 

 

1

 

 

 

1

 

Series B Preferred Stock 5,000,000 shares designated; 9,667 shares issued and outstanding as of September 30, 2026 and December 31, 2025

 

 

1

 

 

 

1

 

Series C Preferred Stock 1,000,000 shares designated; 1,000,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025

 

 

100

 

 

 

100

 

Series D Preferred Stock 20,000,000 shares designated; 876,020 and 198,335 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

 

 

88

 

 

 

20

 

Common stock ($.0001 par value, 1,250,000,000 shares authorized; 223,677,577 and 12,008,725 shares issued and outstanding as of September 30, 2026 and December 31, 2025, and 66 issuable, respectively)

 

 

22,367

 

 

 

1,200

 

Additional paid-in capital

 

 

9,516,584

 

 

 

8,595,711

 

Subscription receivable

 

 

(5,885)

 

 

(5,885)

Accumulated deficit

 

 

(12,180,515)

 

 

(10,721,204)

Total Stockholders' Deficit

 

 

(2,647,259)

 

 

(2,130,056)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

 

$57,506

 

 

$225,901

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 
3

Table of Contents

 

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$4,993

 

 

$4,632

 

 

$15,495

 

 

$7,851

 

Cost of revenue

 

 

979

 

 

 

781

 

 

 

3,128

 

 

 

2,937

 

Gross Profit

 

 

4,014

 

 

 

3,851

 

 

 

12,367

 

 

 

4,914

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

235,592

 

 

 

250,971

 

 

 

594,387

 

 

 

592,246

 

Professional fees

 

 

59,420

 

 

 

17,069

 

 

 

101,372

 

 

 

204,224

 

Depreciation

 

 

1,500

 

 

 

1,500

 

 

 

4,500

 

 

 

2,500

 

Total Operating Expenses

 

 

296,512

 

 

 

269,540

 

 

 

700,259

 

 

 

798,970

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss From Operations

 

 

(292,498)

 

 

(265,689)

 

 

(687,892)

 

 

(794,056)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income

 

 

-

 

 

 

-

 

 

 

5

 

 

 

-

 

Interest expense

 

 

(146,940)

 

 

(14,153)

 

 

(349,735)

 

 

(33,449)

Change in fair value of derivative liabilities

 

 

(1,420,251)

 

 

(201,360)

 

 

(798,637)

 

 

(8,747)

Gain on settlement of debt

 

 

361,374

 

 

 

101,700

 

 

 

376,948

 

 

 

101,700

 

Total Other Income (Expense)

 

 

(1,205,817)

 

 

(113,813)

 

 

(771,419)

 

 

59,504

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Income Taxes

 

 

(1,498,315)

 

 

(379,502)

 

 

(1,459,311)

 

 

(734,552)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$(1,498,315)

 

$(379,502)

 

$(1,459,311)

 

$(734,552)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

 

$(0.01)

 

$(0.04)

 

$(0.02)

 

$(0.08)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Number of Common Shares Outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

 

 

166,810,269

 

 

 

10,239,290

 

 

 

64,903,251

 

 

 

9,419,980

 

  

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 
4

Table of Contents

 

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)

For the Three and Nine months ended September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series A

Preferred stock

 

 

Series B

Preferred stock

 

 

Series C

Preferred stock

 

 

Series D

Preferred stock

 

 

Common stock

 

 

Additional

paid-in

 

 

Subscription

 

 

Accumulated

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

capital

 

 

receivable

 

 

Deficit

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2025

 

 

11,167

 

 

$1

 

 

 

9,667

 

 

$1

 

 

 

1,000,000

 

 

$100

 

 

 

198,335

 

 

$20

 

 

 

12,008,725

 

 

$1,200

 

 

$8,595,711

 

 

$(5,885)

 

$(10,721,204)

 

$(2,130,056)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series D preferred stock issued for compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

66,681

 

 

 

7

 

 

 

-

 

 

 

-

 

 

 

104,993

 

 

 

-

 

 

 

-

 

 

 

105,000

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(111,086)

 

 

(111,086)

Balance, March 31, 2026

 

 

11,167

 

 

 

1

 

 

 

9,667

 

 

 

1

 

 

 

1,000,000

 

 

 

100

 

 

 

265,016

 

 

 

27

 

 

 

12,008,725

 

 

 

1,200

 

 

$8,700,704

 

 

 

(5,885)

 

 

(10,832,290)

 

 

(2,136,142)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series D preferred stock issued for compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

97,377

 

 

 

9

 

 

 

-

 

 

 

-

 

 

 

104,991

 

 

 

-

 

 

 

-

 

 

 

105,000

 

Common stock issued for conversion of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

19,586,449

 

 

 

1,959

 

 

 

90,487

 

 

 

-

 

 

 

-

 

 

 

92,446

 

Common stock issued for compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,000,000

 

 

 

200

 

 

 

8,799

 

 

 

-

 

 

 

-

 

 

 

8,999

 

Common stock issued for service

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,000,000

 

 

 

300

 

 

 

13,200

 

 

 

-

 

 

 

-

 

 

 

13,500

 

Net income for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

150,090

 

 

 

150,090

 

Balance, June 30, 2026

 

 

11,167

 

 

$1

 

 

 

9,667

 

 

$1

 

 

 

1,000,000

 

 

$100

 

 

 

362,393

 

 

$36

 

 

 

36,595,174

 

 

$3,659

 

 

$8,918,181

 

 

$(5,885)

 

$(10,682,200)

 

$(1,766,107)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series D preferred stock issued for compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

513,627

 

 

 

52

 

 

 

-

 

 

 

-

 

 

 

178,448

 

 

 

-

 

 

 

-

 

 

 

178,500

 

Common stock issued for conversion of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

187,082,403

 

 

 

18,708

 

 

 

419,955

 

 

 

-

 

 

 

-

 

 

 

438,663

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,498,315)

 

 

(1,498,315)

Balance, September 30, 2026

 

 

11,167

 

 

$1

 

 

 

9,667

 

 

$1

 

 

 

1,000,000

 

 

$100

 

 

 

876,020

 

 

$88

 

 

 

223,677,577

 

 

$22,367

 

 

$9,516,584

 

 

$(5,885)

 

$(12,180,515)

 

$(2,647,259)

 

For the Three and Nine months ended September 30, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series A

Preferred stock

 

 

Series B

Preferred stock

 

 

Series C

Preferred stock

 

 

Series D

Preferred stock

 

 

Common stock

 

 

Additional

paid-in

 

 

Subscription

 

 

Accumulated

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

capital

 

 

receivable

 

 

Deficit

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2024

 

 

11,167

 

 

$1

 

 

 

9,667

 

 

$1

 

 

 

1,000,000

 

 

$100

 

 

 

72,687

 

 

$7

 

 

 

8,215,426

 

 

$821

 

 

$7,704,343

 

 

$(5,885)

 

$(9,163,306)

 

$(1,463,918)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issued for conversion of Series D preferred stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(8,333)

 

 

(1)

 

 

833,300

 

 

 

83

 

 

 

(82)

 

 

-

 

 

 

-

 

 

 

-

 

Series D preferred stock issued for compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

10,508

 

 

 

1

 

 

 

-

 

 

 

-

 

 

 

89,999

 

 

 

-

 

 

 

-

 

 

 

90,000

 

Reverse split adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(197,136)

 

 

(197,136)

Balance, March 31, 2025

 

 

11,167

 

 

 

1

 

 

 

9,667

 

 

 

1

 

 

 

1,000,000

 

 

 

100

 

 

 

74,862

 

 

 

7

 

 

 

9,048,725

 

 

 

904

 

 

$7,794,260

 

 

 

(5,885)

 

 

(9,360,442)

 

 

(1,571,054)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issued for conversion of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

900,000

 

 

 

90

 

 

 

53,910

 

 

 

-

 

 

 

-

 

 

 

54,000

 

Series D preferred stock issued for compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

15,080

 

 

 

2

 

 

 

-

 

 

 

-

 

 

 

114,998

 

 

 

 

 

 

 

 

 

 

 

115,000

 

Series D preferred stock issued for cash

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

39,868

 

 

 

4

 

 

 

-

 

 

 

-

 

 

 

299,996

 

 

 

-

 

 

 

-

 

 

 

300,000

 

Stock option compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

28,670

 

 

 

-

 

 

 

-

 

 

 

28,670

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(157,914)

 

 

(157,914)

Balance, June 30, 2025

 

 

11,167

 

 

$1

 

 

 

9,667

 

 

$1

 

 

 

1,000,000

 

 

$100

 

 

 

129,810

 

 

$13

 

 

 

9,948,725

 

 

$994

 

 

$8,291,834

 

 

$(5,885)

 

$(9,518,356)

 

$(1,231,298)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issued for conversion of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

990,000

 

 

 

99

 

 

 

40,491

 

 

 

-

 

 

 

-

 

 

 

40,590

 

Series D preferred stock issued for compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

28,698

 

 

 

3

 

 

 

-

 

 

 

-

 

 

 

104,997

 

 

 

-

 

 

 

-

 

 

 

105,000

 

Net loss for the period

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(379,502)

 

 

(379,502)

Balance, September 30, 2025

 

 

11,167

 

 

$1

 

 

 

9,667

 

 

$1

 

 

 

1,000,000

 

 

$100

 

 

 

158,508

 

 

$16

 

 

 

10,938,725

 

 

$1,093

 

 

$8,437,322

 

 

$(5,885)

 

$(9,897,858)

 

$(1,465,210)

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 
5

Table of Contents

 

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOW

(UNAUDITED)

 

 

 

Nine months ended

 

 

 

September 30,

 

 

 

2026

 

 

2025

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$(1,459,311)

 

$(734,552)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Change in fair value of derivative liabilities

 

 

798,637

 

 

 

8,747

 

Amortization of debt discount

 

 

236,453

 

 

 

-

 

Stock based compensation

 

 

410,999

 

 

 

338,670

 

Depreciation

 

 

4,500

 

 

 

2,500

 

Gain on settlement of debt

 

 

(376,948)

 

 

(101,700)

Write-off of security deposit

 

 

2,500

 

 

 

-

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

-

 

 

 

(59)

Inventory

 

 

10,509

 

 

 

(25,113)

Prepaid expense

 

 

(2,415)

 

 

100,000

 

Accounts payable and accrued liabilities

 

 

129,343

 

 

 

51,310

 

Due to related party

 

 

2,978

 

 

 

-

 

Net Cash Used in Operating Activities

 

 

(242,755)

 

 

(360,197)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

Purchase property and equipment

 

 

-

 

 

 

(18,000)

Net Cash Used in Investing Activities

 

 

-

 

 

 

(18,000)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Proceeds from issuance of Series D Preferred Stock

 

 

-

 

 

 

300,000

 

Repayment of convertible notes

 

 

(149,546)

 

 

-

 

Proceeds from convertible notes

 

 

239,000

 

 

 

-

 

Net Cash Provided by Financing Activities

 

 

89,454

 

 

 

300,000

 

 

 

 

 

 

 

 

 

 

Net change in cash

 

 

(153,301)

 

 

(78,197)

Cash at beginning of period

 

 

158,445

 

 

 

137,470

 

Cash at end of period

 

$5,144

 

 

$59,273

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Cash paid for income taxes

 

$-

 

 

$-

 

Cash paid for interest

 

$4,319

 

 

$-

 

 

 

 

 

 

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Derivative liability recognized as debt discount

 

$164,000

 

 

$-

 

Issuance of common stock for conversion of debt

 

$531,109

 

 

$94,590

 

Issuance of common stock for stock payable

 

$-

 

 

$150,000

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 
6

Table of Contents

 

BIOADAPTIVES, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

1. DESCRIPTION OF BUSINESS AND HISTORY

 

Description of business

 

BioAdaptives, Inc. (“BioAdaptives” or the “Company”) was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company’s control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. BioAdaptives’ core business is to investigate, market and distribute natural plant, fungi, and algal based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties.

 

The Company’s corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K filed with SEC on April 14, 2026, have been omitted.

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.

 

Segment Information

 

Our Chief Executive Officer (“CEO”) is the chief operating decision maker who reviews financial information on a consolidated basis for purposes of allocating resources and evaluating financial performance. Accordingly, we determined we operate in a single reporting segment.

 

Our CEO assesses performance and decides how to allocate resources primarily based on consolidated net income, which is reported on our Consolidated Statements of Operations. Total assets on the Consolidated Balance Sheets represent our segment assets.

 

 
7

Table of Contents

 

Inventory

 

Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out (“FIFO”) method and are valued at the lower of cost and net realizable value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As of September 30, 2026 and December 31, 2025, the Company had inventory as follows, and determined that no reserve was required.

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Finished goods

 

$24,865

 

 

$35,207

 

Raw material

 

 

9,332

 

 

 

9,499

 

 

 

$34,197

 

 

$44,706

 

 

Financial Instruments and Fair Value Measurements

 

As defined in ASC 820, “Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

 

The following table summarizes fair value measurements by level as of September 30, 2026 and December 31, 2025, measured at fair value on a recurring basis:

 

 

 

Total Carrying

Value as of

September 30,

 

 

Quoted Market Prices in Active Markets

 

 

Significant Other Observable Inputs

 

 

Significant Unobservable Inputs

 

 

 

2026

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Derivative liabilities

 

$1,861,614

 

 

$-

 

 

$-

 

 

$1,861,614

 

 

 

 

Total Carrying

Value as of

December 31,

 

 

Quoted Market Prices in Active Markets

 

 

Significant Other Observable Inputs

 

 

Significant Unobservable Inputs

 

 

 

2025

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Derivative liabilities

 

$1,738,804

 

 

$-

 

 

$-

 

 

$1,738,804

 

 

 
8

Table of Contents

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used a Black Scholes valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

 

Revenue recognition

 

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

 

 

·

identify the contract with a customer;

 

·

identify the performance obligations in the contract;

 

·

determine the transaction price;

 

·

allocate the transaction price to performance obligations in the contract; and

 

·

recognize revenue as the performance obligation is satisfied.

 

Earnings (loss) per share

 

Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued.

 

For the nine months ended September 30, 2026 and 2025, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

 

(Shares)

 

 

(Shares)

 

Series A Preferred Stock

 

 

55,835

 

 

 

55,835

 

Series B Preferred Stock

 

 

96,670

 

 

 

96,670

 

Series C Preferred Stock

 

 

100,000,000

 

 

 

100,000,000

 

Series D Preferred Stock

 

 

87,602,000

 

 

 

15,850,800

 

Convertible notes

 

 

1,105,869,035

 

 

 

27,719,298

 

Total

 

 

1,293,623,540

 

 

 

143,722,603

 

 

Recent Accounting Pronouncements

 

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.

 

 
9

Table of Contents

 

3. GOING CONCERN

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $12,180,515 as of September 30, 2026. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. Obtaining additional financing, successful development of the Company’s contemplated plan of operations, and the transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

 

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities as of September 30, 2026 and December 31, 2025, consists of the following:

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Accounts payable

 

$32,135

 

 

$13,513

 

Accrued interest

 

 

257,274

 

 

 

218,189

 

Accrued liabilities

 

 

2,781

 

 

 

1,023

 

 

 

$292,190

 

 

$232,725

 

 

5. CONVERTIBLE NOTES

 

Convertible notes as of September 30, 2026 and December 31, 2025, consist of the following:

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

Convertible Notes - originated in April 2018

 

$95,000

 

 

$95,000

 

Convertible Notes - originated in June 2018

 

 

166,000

 

 

 

166,000

 

Convertible Notes - originated in October 2018

 

 

50,000

 

 

 

50,000

 

Convertible Notes - originated in November 2024

 

 

16,200

 

 

 

16,200

 

Convertible Notes - originated in November 2025

 

 

110,200

 

 

 

295,000

 

Convertible Notes - originated in July 2026

 

 

190,100

 

 

 

-

 

Convertible Notes - originated in August 2026

 

 

99,000

 

 

 

-

 

Total convertible notes payable

 

 

726,500

 

 

 

622,200

 

 

 

 

 

 

 

 

 

 

Less: Unamortized debt discount

 

 

(210,613)

 

 

(269,868)

Total convertible notes

 

 

515,887

 

 

 

352,332

 

 

 

 

 

 

 

 

 

 

Less: current portion of convertible notes

 

 

515,887

 

 

 

352,332

 

Long-term convertible notes

 

$-

 

 

$-

 

 

 
10

Table of Contents

 

For the nine months ended September 30, 2026 and 2025, the interest expense on convertible notes was $112,321 and $32,490, respectively. As of September 30, 2026 and December 31, 2025, the accrued interest was $254,098 and $215,973, respectively.

 

The Company recognized amortization expense related to the debt discount of $236,453 and $0 for the nine months ended September 30, 2026 and 2025, respectively, which is included in interest expense in the statements of operations.

 

Conversion

 

During the nine months ended September 30, 2026, the note holders converted principal of $79,000 and accrued interest of $69,878 into 206,668,852 shares of the Company's common stock. As a result, the Company extinguished the related debt obligations and derecognized derivative liabilities of $456,003 and recorded gain on settlement of debt of $73,772.

 

Settlement

 

During the nine months ended September 30, 2026, the Company repaid a convertible note with principal of $105,800 for cash of $149,546 and paid the related accrued interest of $4,318. As a result, the Company extinguished the related debt obligation, wrote off unamortized debt discount of $36,902, derecognized derivative liabilities of $383,824 and recorded a gain on settlement of debt of $303,176.

 

Convertible Notes – Issued during the nine months ended September 30, 2026

 

During the nine months ended September 30, 2026, the Company issued a total principal amount of $289,100 in convertible notes for cash proceeds of $239,000, net of original issue discounts and financing costs of $50,100. The terms of these convertible notes are summarized as follows:

 

 

·

Term approximately 10 months to 1 year;

 

 

 

 

·

Annual interest rates 10 - 12%;

 

 

 

 

·

Convertible at the option of the holders at any time, except for one note which is convertible 180 days after the issuance date;

 

 

 

 

·

Conversion prices are based on 65% of the lowest traded price for the common stock during the 10 or 20 trading days prior to conversion.

 

The Company determined that the conversion features of these convertible notes are derivative liabilities and recognized initial derivative liabilities of $815,070, of which $164,000 was recorded as debt discount and $651,070 was recorded as day one loss on derivative liabilities.

 

 
11

Table of Contents

 

Convertible Notes – Issued during the year ended December 31, 2025

 

During the year ended December 31, 2025, the Company issued a total principal amount of $295,000 in convertible notes for cash proceeds of $255,000. The terms of these convertible notes are summarized as follows:

 

 

·

Term 1 year;

 

 

 

 

·

Annual interest rates 6 - 10%;

 

 

 

 

·

Convertible at the option of the holders at any time

 

 

 

 

·

Conversion prices are based on 60 - 65% of the lowest traded price for the common stock during 20-trading days.

 

In addition, the Company issued a total of 2,062,500 warrants in connection with certain convertible notes. The warrants will expire 3 years after issuance date, and the exercise price of $0.08. The Company determined that the warrants had a fixed monetary value with a variable number of shares at inception and categorized the warrants as a liability, which is derivative liability on the balance sheet.

 

Convertible Notes – Issued during the year ended December 31, 2024

 

On November 5, 2024, the Company issued convertible note of $150,000 for consulting service. The convertible note has a term of 6 months, at an interest rate of 6% per annum. The outstanding principal amount of convertible note and unpaid interest are convertible at the option of the holder at 6 months after the issue date. The conversion price is an average of the closing price during the previous 15-trading days.

 

Convertible Notes – Issued during the year ended December 31, 2018

 

During the year ended December 31, 2018, the Company issued a total principal amount of $426,000 in convertible notes for cash proceeds of $426,000. The convertible notes were also provided with a total of 713 common shares valued at $22,210. The terms of these convertible notes are summarized as follows:

 

 

·

Term two years;

 

 

 

 

·

Annual interest rates 12%;

 

 

 

 

·

Convertible at the option of the holders at any time

 

 

 

 

·

Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price.

 

 
12

Table of Contents

 

6. DERIVATIVE LIABILITIES

 

The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options.

 

Fair Value Assumptions Used in Accounting for Derivative Liabilities.

 

ASC 815 requires us to assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

 

The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of September 30, 2026. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model.

 

For the nine months ended September 30, 2026, the estimated fair values of the liabilities measured on a recurring basis are as follows:

 

 

 

Nine months

ended

 

 

 

September 30,

 

 

 

2026

 

Expected term

 

0.15 - 2.66 years

 

Expected average volatility

 

221% - 496%

 

Expected dividend yield

 

 

-

 

Risk-free interest rate

 

3.72%-5.00%

 

 

The following table summarizes the changes in the derivative liabilities during the nine months ended September 30, 2026.

 

Balance - December 31, 2025

 

$1,738,804

 

 

 

 

 

 

Addition of new derivatives recognized as debt discounts

 

 

164,000

 

Addition of new derivatives recognized as loss on derivatives

 

 

651,070

 

Settled on issuance of common stock

 

 

(456,003)

Extinguished upon repayment of convertible note

 

 

(383,824)

Loss on change in fair value of the derivative

 

 

147,567

 

Balance - September 30, 2026

 

$1,861,614

 

 

The aggregate loss on derivatives during the nine months ended September 30, 2026 and 2025 was as follows.

 

 

 

Nine months ended

 

 

 

September 30,

 

 

 

2026

 

 

2025

 

Day one loss due to derivative liabilities on convertible notes

 

$651,070

 

 

$-

 

Loss on change in fair value of the derivative liabilities

 

 

147,567

 

 

 

8,747

 

 

 

$798,637

 

 

$8,747

 

 

 
13

Table of Contents

 

7. STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

On March 13, 2025, the increase in number of preferred shares from 10,000,000 to 31,000,000 having the par value of 0.0001 per share was authorized by written consent of the holders of a majority of our outstanding voting stock.

 

The Company is authorized to issue 31,000,000 shares of preferred stock, $0.0001 par value per share, of which 4,000,000 have been designated as Series A Preferred Stock, 5,000,000 have been designated as Series B Preferred Stock, 1,000,000 have been designated as Series C Preferred Stock and 20,000,000 have been designated as Series D Preferred Stock.

 

Series A Preferred Stock

 

On February 6, 2020, the Company established its Series A Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series A Preferred Stock.

 

The Company may use the Series A Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series A Preferred Stock have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 5:1 ratio.

 

As of September 30, 2026 and December 31, 2025, 11,167 shares of Series A Preferred Stock are issued and outstanding.

 

Series B Preferred Stock

 

On January 24, 2022, the Company established its Series B Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 5,000,000 shares of Series B Preferred Stock.

 

The Company may use the Series B Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series B Preferred Stock have enhanced voting privileges (10:1); the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 10:1 ratio.

 

As of September 30, 2026 and December 31, 2025, 9,667 shares of Series B Preferred Stock are issued and outstanding.

 

Series C Preferred Stock

 

On January 24, 2022, the Company established its Series C Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 1,000,000 shares of Series C Preferred Stock.

 

 
14

Table of Contents

 

The Company may use the Series C Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series C Preferred Stock have enhanced voting privileges (1000:1); the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 100:1 ratio.

 

During the nine months ended September 30, 2026, there was no issuance of Series C shares.

 

As of September 30, 2026 and December 31, 2025, 1,000,000 shares of Series C Preferred Stock are issued and outstanding.

 

Series D Preferred Stock

 

On July 4, 2024, the Company established its Series D Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 20,000,000 shares of Series D Preferred Stock.

 

The holders may convert the Series D Preferred Stock to Common Stock at a rate of 100 shares of common stock for each share of Series D Preferred Stock. Each Series D Preferred Stock carries the voting rights equal to 100 shares of Common Stock.

 

During the nine months ended September 30, 2026, the Company issued 677,685 shares of Series D Preferred stock valued at $388,500, of which 607,627 shares valued at $315,000 were issued to management for compensation and 70,058 shares valued at $73,500 were issued to an employee for services.

 

As of September 30, 2026 and December 31, 2025, 876,020 and 198,335 shares of Series D Preferred Stock are issued and outstanding, respectively.

 

Common Stock

 

The Company is authorized to issue 1,250,000,000 shares of Common Stock, 0.0001 par value per share.

 

During the nine months ended September 30, 2026, the Company issued an aggregate of 211,668,852 shares of common stock as follows;

 

 

·

206,668,852 shares issued upon the common stock for conversion of debt.

 

·

2,000,000 shares issued for compensation, valued at $8,999.

 

·

3,000,000 shares issued for services, valued at $13,500.

 

As of September 30, 2026 and December 31, 2025, there were 223,677,577 and 12,008,725 shares of the Company’s common stock issued and outstanding. In addition, as of September 30, 2026 and December 31, 2025, there were 66 shares of the Company’s common stock issuable.

 

 
15

Table of Contents

 

Stock Option

 

The following is a summary of the change in stock option during the nine months ended September 30, 2026:

 

 

 

Options Outstanding

 

 

Weighted Average

 

 

 

Number of

 

 

Weighted Average

 

 

Remaining life

 

 

 

Options

 

 

Exercise Price

 

 

(years)

 

 

 

 

 

 

 

 

 

 

 

Outstanding, December 31, 2025

 

 

500,000

 

 

$10.00

 

 

 

9.30

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited/canceled

 

 

-

 

 

 

-

 

 

 

-

 

Outstanding, September 30, 2026

 

 

500,000

 

 

$10.00

 

 

 

8.55

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable options, September 30, 2026

 

 

500,000

 

 

$10.00

 

 

 

8.55

 

 

The intrinsic value of the options as of September 30, 2026, is $0.

 

8. RELATED PARTY TRANSACTIONS

 

Due to related party

 

As of September 30, 2026, the Company recorded due to a related party of $2,978 for the payment of operating expenses on behalf of the Company. This amount is non-interest bearing and due on demand.

 

Employee agreements

 

In May 2024, the Company entered into an employment agreement with our chief executive officer. The Company agrees to pay a salary of $300,000 per annum. During the nine months ended September 30, 2026 and 2025, the Company recorded payroll expense of $225,000 and the Company issued 434,013 and 40,413 shares of Series D Preferred Stock for payroll, respectively.

 

In May 2024, the Company entered into an employment agreement with our director. The Company agrees to pay a salary of $5,000 per month. During the nine months ended September 30, 2026 and 2025, the Company recorded payroll expense of $45,000, and the Company issued 86,807 and 7,411 shares of Series D Preferred Stock for payroll, respectively.

 

In January 2025, the Company entered into an employment agreement with our director. The Company agrees to pay a salary of $5,000 per month. During the nine months ended September 30, 2026 and 2025, the Company recorded payroll expense of $45,000 and $40,000, respectively, and the Company issued 86,807 and 6,462 shares of Series D Preferred Stock for payroll, respectively.

 

9. NOTES PAYABLE

 

During the year ended December 31, 2024, the Company issued notes payable of $32,096. The note is a 4% interest bearing promissory note that the term is 1 year.

 

During the nine months ended September 30, 2026, the Company recorded notes payable of $32,096, interest expense of $961, and accrued interest of $3,177 and $2,216, respectively, as of September 30, 2026 and December 31, 2025.

 

 
16

Table of Contents

 

10. COMMITMENTS AND CONTINGENCIES

 

Short-term Leases

 

The Company has not entered into any long-term leases, contracts, or commitments. In November 2023, the Company leased an office for a month-to-month term. During the nine months ended September 30, 2026 and 2025, the Company incurred rent expense of $600 and $0, respectively. The Company had security deposit of $2,500 as of December 31, 2025. During the nine months ended September 30, 2026, the security deposit was written off, resulting in a balance of $0 as of September 30, 2026.

 

11. SUBSEQUENT EVENTS

 

On October 29 2026, BioAdaptives. Inc executed a purchase agreement with Xycota Biosciences, LLC, a preclinical biotechnology company, which goal is an oral psilocybin treatment that patients could take at home without hallucinogenic effects. At closing, Xycota would become a wholly owned subsidiary of BioAdaptives and continue under its existing executive and scientific leadership. This acquisition gives stockholders a defined path into CNS biotechnology, with Xycota operating separately, funding tied to closing and milestones. The agreement also provided a possible nutraceutical spin-off. For further details of this transaction, refer to 8K filed on November 4, 2026.

 

 
17

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

FORWARD LOOKING STATEMENTS

 

This current report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

 

Our financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

 

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

 

As used in this quarterly report, the terms “we”, “us”, “our”, “Company” and "BioAdaptives" mean BioAdaptives Inc., unless otherwise indicated.

 

1. OUR BUSINESS

 

Overview

 

BioAdaptives' core business is to investigate, market, and distribute natural plant, algal, and cyanobacteria-based products and medical devices that enhance health and wellness for humans and animals, with a focus on nootropics, anti-aging, weight control, relaxation, pain relief, and anti-viral benefits. BioAdaptives is reformulating its entire product line and started bringing out new products from the second quarter of 2025.

 

Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared Class Tl medical device, the Lung Flute™. In April 2024, The Company negotiated with the sole owner of the product to assume their existing stock and their rights to all future activities on this item. It intends to actively expand its sales efforts beyond the direct sales effort of its Lung Cleanser to target medical communities, pharmacies, gyms, athletic clubs, and senior communities, both in the US and internationally. The Company is also exploring agreements with other medical device manufacturers, the owners of intellectual property related to medical devices and processes, as well as marketing companies associated with these manufacturers and owners.

 

 
18

Table of Contents

 

The Company's current products in development include dietary supplements utilizing natural ingredients and proprietary methods to optimize the availability of nutrients in foods and beverages. The human products are designed to aid in cognitive health, regenerative stem cell activation, and healthy weight loss. MyndMed™ provides immediate cognitive enhancement (focus, clarity, motivation), medium-term resilience and memory gains, and long-term neuroprotection and cognitive health, making it a robust solution for anyone seeking to optimize mental performance and brain longevity. Its partner, MyndRenew™ is a premium nighttime formula designed to support overnight restoration, help you recover from demanding days, and prepare you for next-day mental performance. Zeranovia™ is a healthy weight loss enhancer. Xcellara™ is BioAdaptives’ regenerative wellness solution to enhance your performance, accelerate recovery, and revitalize your health.

 

Beginning in April 2025, the Company completed preparations to launch the Canine Product – PawPa®Regen. Backed by science and advanced technology, PawPa®’s products not only enhance pet wellness, but also set the new standard in pet care. “Regen” dog chew PawPa®’s flagship product is crafted with a blend of advanced nutraceutical compounds and infused with all-natural ingredients; these chews are specially formulated to enhance canines’ quality of life in their golden years. Specific benefits of the “Regen” chew include Regenerative Support, Energy & Vitality, and Anti-aging Benefits.

 

The Company’s Product MyndMed™ completed its pre-launch phase in November 2025. MyndMed™ is designed to optimize multiple neurotransmitter systems and neuroprotective pathways, delivering broad-spectrum cognitive benefits. By synergistically targeting acetylcholine, dopamine, neuroprotection, synaptic growth, and stress reduction, MyndMed™ supports both immediate and sustained improvements in mental performance, resilience, and brain health. It aids in a rapid increase in motivation, sustained attention, and mental clarity, and helps in tackling demanding cognitive tasks with greater drive and efficiency. The product underwent rigorous testing by TruShield and received its TruShield Certified Certification, which provides the brand with a trusted, science-backed way to demonstrate that the product is free from banned substances. Joining MyndMed™™ is MyndRenew.™ a nighttime dietary supplement formulated to support sleep quality and the brain's natural overnight recovery processes. MyndRenew™ is the nighttime component of the Company's MyndSystem™ platform — a first-of-its-kind approach to cognitive support that spans the full 24-hour cycle. It also underwent rigorous testing by TruShield and received its TruShield Certified Certification, This 24-hour MyndSystem platform was launched in the end of this quarter.

 

Xcellara™ BioAdaptives’ regenerative wellness solution to enhance performance, accelerate recovery, and revitalize health is Backed by double-blind placebo-controlled clinical trials, Xcellara™ activates stem cells for cellular regeneration. Derived from a proprietary blend of nutraceutical compounds, Xcellara™ is the secret weapon for success on and off the court, providing a myriad of benefits. In its market testing, Xcellera™ has demonstrated a positive effect on individuals challenged by chronic fatigue. To expand the success and possibilities we see in Xcellara™, a collection of products based on Xcellara™ researches are being expanded into an Xcellara™ platform. The first new product in this Platform is Xcellara-Heart™. The new formula combines the company's stem/progenitor cell mobilization platform with Tanshinone IIA, a compound studied in cardiovascular signaling research. The launch expands BioAdaptives' portfolio of targeted wellness supplements and represents another step in the company's strategy of building products around its Xcellara™ platform. The Company is looking to add another 4 science rich products based on the Xcellara™ platform in 2027: XcellaraNeuro™ that supports cognitive function, the body's natural stem cell mobilization and healthy neural tissue. XcellaraDerm™ which supports skin health and appearance as well as the body's natural stem cell mobilization and collagen matrix integrity. XcellaraPrime™, the clinically proven Xcellara™ mobilizer combined with NAD+ precursors and longevity co-factors for adults 35+ seeking comprehensive cellular support. XcellaraResilience™, supports healthy cortisol levels and stress resilience, as well as HPA axis regulation and adrenal function, plus assists in the body's natural stem cell mobilization and cognitive function under stress

 

 
19

Table of Contents

 

Zeranovia™ has been going through a further refining process. It is about to complete its clinical trial for launching in the 2027. Zeranovia™ is an innovative, natural weight loss supplement designed to work exceptionally well on its own or as a complement to GLP-1 and GIP weight loss treatments such as Ozempic, Wegovy, Zepbound, and Mounjaro. It supports weight loss by dramatically suppressing appetite, enhancing insulin sensitivity, preserving muscle mass, and delivering essential nutrients. Zeranovia™ significantly improves the effectiveness of existing treatments while providing substantial nutritional support to prevent muscle wasting during a caloric deficit. Throughout the trial, extremely encouraging results have been reported of participants losing 5 to 11 pounds in a 7 to 10 day period.

 

Market and Marketing

 

BioAdaptives Inc. has developed a robust Direct to Consumer (DTC) digital marketing campaign to connect directly with its target audience. Leveraging platforms like social media, email marketing, and user-friendly websites, the company promotes its supplement products with engaging content tailored to health-conscious consumers. Through targeted ads, informative blog posts, and compelling calls-to-action, BioAdaptives ensures its messaging resonates, driving awareness and conversions while fostering a community around wellness and natural health solutions.

 

In addition to its DTC efforts, BioAdaptives has forged strategic partnerships within the telehealth industry to enhance its product offerings. By aligning its supplements as both companion products and standalone solutions, the company integrates seamlessly with telehealth platforms, providing participants with accessible, science-backed options to support their wellness journeys. These collaborations not only expand BioAdaptives’ reach but also position our products as trusted recommendations within virtual healthcare ecosystems, capitalizing on the growing demand for telehealth services.

 

In the past year, the Company also placed its PawPa™ Regen™ Dog Treats with Amazon and started limited advertising efforts there. It has shown slow progress.

 

Finally, BioAdaptives employs a dynamic affiliate marketing program, partnering with companies and individual influencers who boast large social media following and proven success in the supplement industry. These affiliates, carefully selected for their credibility and performance, promote BioAdaptives’ products through authentic endorsements, affiliate links, and promo codes. This strategy amplifies brand visibility, drives sales, and builds trust among niche audiences, leveraging the influence of established voices in the health and wellness space to accelerate growth.

 

Manufacturing

 

All of the Company's nutraceutical products are considered dietary supplements or natural foods, and we carefully avoid making health, drug, or disease cure claims that could trigger regulatory compliance issues and affect our ability to market BioAdaptives products. Our active ingredients are all plant, fungi, algal, or cyanobacteria-based and sourced worldwide from reputable suppliers who employ stringent compliance and sustainable agriculture practices.

 

BioAdaptives actively investigates new products, techniques, and novel applications of existing products or technology in our research. The Company's research has focused on investigating all-natural supplement formulations that activate primitive cells, including stem cells and their derivatives, and natural ingredients that encourage stem cell proliferation. In 2022, the Company started a product line utilizing cyanobacteria and mushrooms. Since 2025, the Company has actively researched and started testing and manufacturing a line of neuro-performance and repair product.

 

With regard to medical devices, in April 2024, we purchased the Lungflute™ from the sole US affiliate of the patent holder. We do not expect to develop any direct capability to manufacture medical devices for numerous reasons, including a lack of capital and the fact that the amortized cost of such facilities, if we were to construct or acquire them, is generally far higher compared to the cost of purchasing a finished product. We operate as a Research and Development nutraceutical company.

 

 
20

Table of Contents

 

Employees

 

Currently, the Company has one full-time executive employee. We retain hourly labor as needed and professional consultants to operate our business. The company's management expects to use outside consultants, attorneys, and accountants as necessary. The need for additional employees and their availability will be addressed when deciding whether to acquire or participate in specific business opportunities.

 

2. LIQUITITY AND CAPITAL RESOURCES:

 

Liquidity -- Financial Performance – Three Months Ended September 30 2026, and 2025

We had a net loss of $ 1,498,315 for the three-month period ended September 30, 2026, which lost $1,118,813more than the net loss of $ 379,502 for the three-month period ended September 30, 2025. The change in our results is mainly due to the Change in the value of derivatives liabilities.

 

The following table summarizes key items of comparison and their related increase (decrease) for the three-month periods ended June 30, 2026 and 2025.

 

 

 

September 30,

2026

 

 

September 30,

2025

 

 

Changes

 

Revenue

 

 

4,993

 

 

 

4,632

 

 

 

361

 

Cost of Sales

 

 

979

 

 

 

781

 

 

 

(198)

Operation Expenses

 

 

296,512

 

 

 

269,540

 

 

 

(26,972)

Other income (expenses)

 

 

(1,420,251)

 

 

(113,813)

 

 

(1,306,438)

Net Income (loss)

 

 

(1,498,315)

 

 

(379,502)

 

 

(1,118,813)

 

Revenue 

 

PawPa™ Regen dog treats, started limited sales via its website and Amazon. It is still going through its market testing. MyndSystem™ started its test marketing in May and is still evolving into its new bundle. While Xcellara™ has slowly started its marketing.

 

Cost of Sales

Cost of Sales covers these sales.

 

Operation Expenses

Our general, administrative and professional fees are largely attributable to office, rent, advertising, consultants and transfer agent, legal, accounting and audit fees related to our reporting requirements as a public company as well as stock-based compensation for officers, directors and consultants.

 

Other Income (Expense) ($ 1,205,817) and ($ 113,813) for the three months ended September 30, 2026, and 2025. It also shows a change in fair value of derivative liabilities of $1,420,251 and $ 201,360 for September 30, 2026, and 2025.

 

Net Loss

As a result of our change in the fair value of the derivatives liabilities the Company reported a net loss of $1,498.315 and a net loss of $379,502 for the three months ended September 30, 2026, and 2025.

 

 
21

Table of Contents

 

Capital Resources – Balance Sheet and Cash Flows

Our balance sheet as of September 30, 2026 reflects current assets of $ 48,006 , including cash in the amount of $5,144.

 

Working Capital (Deficiency)

 

 

 

September 30,

2026

 

 

September 30,

2025

 

 

Change

 

 

 

 

 

 

 

 

 

 

 

Current Assets

 

$48,006

 

 

$108,860

 

 

$(60,854)

Current Liabilities

 

$(2,204,765)

 

$(1,589,570)

 

$(615,195)

Working Capital (Deficiency)

 

$(1,766,107)

 

$(1,465,107)

 

$(301,810)

 

 

 

Nine Months Ended

September 30

 

 

 

 

 

 

2026

 

 

2025

 

 

Change

 

Cash used in Operating Activities

 

$242,755

 

 

$360,197

 

 

$117,442

 

Cash used in Investing Activities

 

 

-

 

 

 

-

 

 

 

-

 

Cash provided by Financing Activities

 

 

89,454

 

 

 

300,000

 

 

$(219,546)

 

Net cash used by operating activities during the six months ended September 30, 2026 was $242,755 a decrease of $ 117,442 from net cash used of $360,197 in operating activities during the three months ended September 30, 2025

 

As of September 30, 2026, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, as well as the sales of our various new product lines, which may be insufficient to fund our capital expenditure, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

 

On September 30 2026, we had $ 5.144 of cash on-hand and an accumulated deficit of $ 12,180,515, and as noted throughout this report and our financial statements and notes thereto, our independent auditors expressed their substantial doubt as to our ability to continue as a going concern as of December 31, 2025. We anticipate to be incurring some losses in the near future, until all the products are launched and have maximized their sales. Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means.

 

Because our business plan relies on marketing products, our capital requirements are generally limited to general operations, administration, inventories, and development expenses including the costs of continuing as a public company, and our variable costs scale up or down based on our actual sales. We believe that increasing our marketing expenses will be critical to establishing sales sufficient to cover our expenses and, if possible, generate a profit. We anticipate using our existing financing operations to do so, which will almost certainly require either the issuance of equity or increases in existing levels of debt or, most likely, both.

 

 
22

Table of Contents

 

Management's plans include the raising of capital through the equity markets to fund future operations, seeking additional acquisitions, and generating revenue through our business. However, even if we do raise sufficient capital to support our operating expenses and generate adequate revenues, there can be no assurances that the revenue will be sufficient to enable us to develop business to a level where we will generate profits and positive cash flows from operations. These matters raise substantial doubt about our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

 

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, and capital expenditures or capital resources that are material to stockholders.

 

Critical Accounting Policies

Our financial statements are based on the application of accounting principles generally accepted in the United States ("US GAAP"). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue, and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to US GAAP and are consistently and conservatively applied that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

 

Recent Accounting Pronouncements

The Company has evaluated recent pronouncements through Accounting Standards Updates ("ASU") and believes that none of them will have a material impact on the Company's financial position, results of operations or cash flows.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a “smaller reporting company,” we are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report, June 30, 2026. This evaluation was carried out under by our Chief Executive Officer.

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company's reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

Based upon that evaluation, including our Chief Executive Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report due to a material weakness in our internal control over financial reporting, which is described below.

 

 
23

Table of Contents

 

Management's Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of September 30, 2026 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of September30, 2026, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment. and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

 

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending December 31, 2026: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (a) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

To a certain extent, the size of our operation provides inherent checks and balances relative to internal controls: Because of our limited staff size and the integration of our executives and directors in operations, the prospect for significant internal control failures resulting in unreliable financial statements or worse is remote. Regardless, we recognize the importance of multiple layers of reporting and controls and are working toward improving our capabilities.

 

Changes in Internal Control over Financial Reporting

 

There was no change in the Company's internal control over financial reporting that occurred during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

 

 
24

Table of Contents

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

At this time, we know of no pending legal proceedings to which we are a party, either individually or in the aggregate. We are from time-to-time, during the normal course of our business operations, subject to various litigation claims and legal disputes. There are no such claims or disputes pending at this time and we have not been notified of any possible claims or disputes.

 

Item 1A. Risk Factors

 

As a “smaller reporting company”, we are not required to provide the information required by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None

 

Item 3. Defaults Upon Senior Securities

 

The Company has no senior securities, but has outstanding instruments previously characterized as unsecured convertible debentures. These instruments are not senior to any other Company obligation. The Company arranged extension and forbearance agreements with the holders of the 12% Debentures, which were issued in 2018 and were due at various times in 2020. Our agreement called for the extension of these obligations on the same terms until December 31, 2021, in exchange for current interest payments and delivery of 280,000 shares of its common stock (total). We are currently in default on these obligations but are working on an alternative resolution.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

Nothing to add.

 

 
25

Table of Contents

 

Item 6. Exhibits

 

31.1

 

Section 302 Certification by the Principal Executive Officer

 

 

 

31.2

 

Section 302 Certification by the Principal Financial Officer

 

 

 

32.1

 

Section 906 Certification by the Principal Executive Officer

 

 

 

32.2

 

Section 906 Certification by the Principal Financial Officer

 

 
26

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BioAdaptives Inc.

(Registrant)

    

Dated: November 16, 2026

/s/ James E. Keener

 

 

James E. Keener

 
  

Chief Executive Officer

 

 

 

 

 

 

 

/s/ James E. Keener

 

 

 

James E. Keener

 

 

 

Principal Financial Office

 

 

 
27

 

Keep reading